- Inhibitory Selectivity
|Catalog No.||Product Name||Solubility(25°C)|
|S1354||Lansoprazole||<1 mg/mL||74 mg/mL||14 mg/mL|
|S1389||Omeprazole||<1 mg/mL||69 mg/mL||13 mg/mL|
|S1413||Bafilomycin A1(Baf-A1)||<1 mg/mL||6 mg/mL||<1 mg/mL|
|S1743||NEXIUM (esomeprazole magnesium)||<1 mg/mL||143 mg/mL||143 mg/mL|
|S4075||Zinc Pyrithione||<1 mg/mL||30 mg/mL||<1 mg/mL|
|S4845||Rabeprazole||71 mg/mL||71 mg/mL||71 mg/mL|
|S5058||Revaprazan Hydrochloride||-1 mg/mL||16 mg/mL||-1 mg/mL|
|S3666||Ilaprazole||<1 mg/mL||73 mg/mL||14 mg/mL|
|S2222||PF-3716556||<1 mg/mL||79 mg/mL||79 mg/mL|
|S4099||Dexlansoprazole||<1 mg/mL||74 mg/mL||<1 mg/mL|
|S4212||Tenatoprazole||<1 mg/mL||46 mg/mL||14 mg/mL|
|S4665||Rebeprazole sodium||76 mg/mL||76 mg/mL||76 mg/mL|
|S4538||Pantoprazole sodium||81 mg/mL||81 mg/mL||81 mg/mL|
|S2105||Pantoprazole||<1 mg/mL||76 mg/mL||76 mg/mL|
- Proton Pump Inhibitors (14)
- New Proton Pump Products
|Catalog No.||Information||Product Use Citations||Product Validations|
Lansoprazole is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid.
Omeprazole is a proton pump inhibitor, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.
Bafilomycin A1 is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM.
Expressions of LC3-I and LC3-II in protein were detected by Western blotting. Bafilomycin A1 significantly inhibited the effect of PNU282987 on LC3-II/I ratio in LPS-stimulated BV2 microglia (n = 6 per group).
Esomeprazole Magnesium is a proton pump inhibitor to reduce gastric acid secretion.
Zinc pyrithione is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump.
Rabeprazole is an oral inhibitor of proton pump and blocks the production of acid by the stomach.
Revaprazan Hydrochloride is a new reversible proton pump inhibitor with long-lasting acid-suppressive effects.
Ilaprazole is a new proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. It inhibits H+/K+-ATPase with an IC50 of 6.0 μM.
PF 3716556 is a potent and selective P-CAB (potassium-competitive acid blocker), with pIC50 of 6.026 and 7.095 for the inhibition of porcine H+,K+-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na+,K+-ATPase, used for the treatment of gastroesophageal reflux disease.
Dexlansoprazole, the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties.
Tenatoprazole is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM.
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors.
Pantoprazole is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.
Pantoprazole is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.